JPH07502490A - 殺菌性/透過性増大タンパク質および脂質担体を含有する組成物、その製造方法、およびそれらの使用 - Google Patents
殺菌性/透過性増大タンパク質および脂質担体を含有する組成物、その製造方法、およびそれらの使用Info
- Publication number
- JPH07502490A JPH07502490A JP5506407A JP50640793A JPH07502490A JP H07502490 A JPH07502490 A JP H07502490A JP 5506407 A JP5506407 A JP 5506407A JP 50640793 A JP50640793 A JP 50640793A JP H07502490 A JPH07502490 A JP H07502490A
- Authority
- JP
- Japan
- Prior art keywords
- permeability
- bactericidal
- protein
- lipopolysaccharide
- enhancing protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
- F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
- F02B75/00—Other engines
- F02B75/02—Engines characterised by their cycles, e.g. six-stroke
- F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
- F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four
Abstract
Description
Claims (15)
- 1.殺菌性/透過性増大タンパク質および脂質担体を含有する組成物であって、 殺菌性/透過性増大タンパク質が脂質担体に溶解している組成物。
- 2.脂質担体がリボソームを含有する請求の範囲第1項記載の組成物。
- 3.脂質担体が非イオン性界面活性剤を含有する請求の範囲第1項記載の組成物 。
- 4.請求の範囲第1項記載の組成物の製造方法であって、殺菌性/透過性増大タ ンパク質と脂質担体とを、殺菌性/透過性増大タンパク質が溶解するような条件 下で接触させることを包含する方法。
- 5.治療上有効な量の殺菌性/透過性増大タンパク質および薬剤学的に許容し得 る脂質担体を含有する医薬組成物であって、殺菌性/透過性増大タンパク質が脂 質担体中に溶解している組成物。
- 6.薬剤学的に許容し得る脂質担体がリポソームを含有する請求の範囲第5項記 載の組成物。
- 7.薬剤学的に許容し得る脂質担体が非イオン性界面活性剤を含有する請求の範 囲第5項記載の組成物。
- 8.請求の範囲第5項記載の医薬組成物の製造方法であって、治療上有効な量の 殺菌性/透過性増大タンパク質と薬剤学的に許容し得る脂質担体とを、殺菌性/ 透過性増大タンパク質が溶解するような条件下で接触させることを包含する方法 を提供する。
- 9.試料中のリポ多糖の検出方法であって、試料と請求の範囲第1項記載の組成 物とを、リポ多糖−殺菌性/透過性増大タンパク質複合体が形成されるような条 件下で接触させ、かっリポ多糖−殺菌性/透過性増大タンパク質復合体を検出し 、それにより試料中のリポ多糖を検山することを包含する方法。
- 10.試料中のリポ多糖の量を定量的に測定する方法であって、試料と請求の範 囲第1項記載の組成物とを、リポ多糖−殺菌性/透過性増大タンパク質複合体が 形成されるような条件下で接触させ、かつリポ多糖−殺菌性/透過性増大タンパ ク質複合体の量を定量的に測定し、それにより試料中のリポ多糖の量を定量的に 測定する方法。
- 11.殺菌性/透過性増大タンパク質が非結合リポ多糖と複合体を形成し得るよ うに手術用具を殺菌性/透過性増大タンパク質で被覆する方法であって、請求の 範囲第5項記載の医薬組成物と生物学的試料に接触することが想定された用具表 面とを、含有される殺菌性/透過性増大タンパク質が用具表面に付着するような 条件下で接触させることを包含する方法。
- 12.殺菌性/透過性増大タンパク質が非結合リポ多糖と複合体を形成し得るよ うに移植可能な侵入性装置を殺菌性/透過性増大タンパク質で被覆する方法であ って、請求の範囲第5項記載の医薬組成物と生物学的試料と接触することが想定 された装置表面とを、含有される殺菌性/透過性増大タンパク質が装置表面に付 着するような条件下で接触させることを包含する方法。
- 13.リポ多糖を含有する流体を、該流体を患者に投与する前に浄化する方法で あって、流体と請求の範囲第5項記載の医薬組成物とを、リポ多糖と含有される 殺菌性/透過性増大タンパク質とが複合体を形成するような条件下で接触させ、 かっ形成された複合体を流体から分離し、それにより流体を浄化することを包含 する方法。
- 14.内毒素関連ショック、内毒素関連播種性血管内凝固、内毒素関連貧血、内 毒素関連血小板減少症、内毒素開運成人呼吸窮迫症候群および内毒素関連腎不全 からなる群より選ばれる疾患に罹患した患者を治療する方法であって、患者に請 求の範囲第5項記載の医薬組成物を、含有される殺菌性/透過性増大タンパク質 が患者の有するリポ多糖と結合し得るに有効な量投与し、それにより患者を治療 することを包含する方法。
- 15.患者における内毒素血症を予防する方法であって、患者に請求の範囲第5 項記載の医薬組成物を、含有される殺菌性/透過性増大タンパク質が患者の与す るリポ多糖と結合し得るに有効な量投与し、それにより患者における内毒素血症 を予防することを包含する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US766,566 | 1991-09-27 | ||
US07/766,566 US5234912A (en) | 1989-02-14 | 1991-09-27 | Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof |
PCT/US1992/008234 WO1993005797A1 (en) | 1991-09-27 | 1992-09-28 | Compositions comprising a bactericidal/permeability increasing protein and a lipid carrier, methods of making same, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH07502490A true JPH07502490A (ja) | 1995-03-16 |
Family
ID=25076825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5506407A Pending JPH07502490A (ja) | 1991-09-27 | 1992-09-28 | 殺菌性/透過性増大タンパク質および脂質担体を含有する組成物、その製造方法、およびそれらの使用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US5234912A (ja) |
EP (1) | EP0610445B1 (ja) |
JP (1) | JPH07502490A (ja) |
AU (1) | AU664206B2 (ja) |
CA (1) | CA2119262C (ja) |
DE (1) | DE69327516T2 (ja) |
WO (1) | WO1993005797A1 (ja) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6265187B1 (en) | 1989-02-14 | 2001-07-24 | Incyte Pharmaceuticals, Inc. | Recombinant endotoxin-neutralizing proteins |
US6093801A (en) * | 1989-02-14 | 2000-07-25 | Incyte Pharmaceuticals, Inc. | Recombinant analogs of bactericidal/permeability increasing protein |
US5627262A (en) * | 1989-07-05 | 1997-05-06 | The Board Of Regents Of The University Of Oklahoma | Method and composition for the treatment of septic shock |
US5607916A (en) * | 1989-07-05 | 1997-03-04 | The Board Of Regents Of The University Of Oklahoma | Method and composition for the treatment of septic shock |
US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
CA2112776C (en) * | 1993-01-21 | 2002-11-12 | Masakazu Tsuchiya | Process for inhibiting activity of endotoxin |
US5420019A (en) * | 1993-02-02 | 1995-05-30 | Xoma Corporation | Stable bactericidal/permeability-increasing protein muteins |
EP0682524B1 (en) * | 1993-02-02 | 2001-10-04 | XOMA Technology Ltd. | Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant |
US5652332A (en) * | 1993-03-12 | 1997-07-29 | Xoma | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
US6214789B1 (en) | 1993-03-12 | 2001-04-10 | Xoma Corporation | Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products |
JPH08511682A (ja) * | 1993-04-30 | 1996-12-10 | インサイト ファーマシューティカルズ,インク. | 組み換えbpi蛋白およびlbp蛋白、それをコードする核酸分子、その生産方法並びにそれらの使用 |
WO1995000641A1 (en) | 1993-06-17 | 1995-01-05 | Xoma Corporation | Lipopolysaccharide binding protein derivatives |
US5770561A (en) * | 1993-07-14 | 1998-06-23 | Xoma Corporation | Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products |
WO1995002414A1 (en) * | 1993-07-14 | 1995-01-26 | Xoma Corporation | Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products |
US6159936A (en) * | 1993-07-20 | 2000-12-12 | The Regents Of The University Of California | Compositions and methods for treating and preventing microbial and viral infections |
US6653442B1 (en) | 1993-07-20 | 2003-11-25 | Intrabiotics Pharmaceuticals, Inc. | Protegrins |
US5804558A (en) * | 1993-07-20 | 1998-09-08 | University Of California | Protegrins |
CN1133634A (zh) * | 1993-09-22 | 1996-10-16 | 爱克斯欧玛公司 | 定量体液中的bpi的方法 |
US5523288A (en) * | 1993-09-22 | 1996-06-04 | Xoma Corporation | Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (BPI) protein product and antibiotic |
US6759203B1 (en) | 1993-09-22 | 2004-07-06 | Xoma Corporation | Method for quantifying BPI in body fluids |
ATE269099T1 (de) * | 1993-10-15 | 2004-07-15 | Xoma Technology Ltd | Bpi-protein-produkte für definierte funktionen des reticuloendothelialen systems |
US5624904A (en) * | 1993-11-17 | 1997-04-29 | Massachusetts Institute Of Technology | Method for treating gram positive septicemia |
ATE219684T1 (de) * | 1994-01-14 | 2002-07-15 | Xoma Technology Ltd | Anti gram positive bakterielle verfahren und mittel |
EP0754049B1 (en) * | 1994-01-14 | 2002-04-03 | XOMA Technology Ltd. | Anti-fungal methods and materials |
US5643875A (en) * | 1994-01-24 | 1997-07-01 | Friedmann; Nadav | Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products |
US5830860A (en) * | 1994-03-24 | 1998-11-03 | Regents Of The University Of Minnesota | Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use |
US5786324A (en) * | 1994-03-24 | 1998-07-28 | Regents Of The University Of Minnesota | Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use |
US5578568A (en) | 1994-04-22 | 1996-11-26 | Xoma Corporation | Method of treating conditions associated with intestinal ischemia/reperfusion |
US5932544A (en) | 1994-05-31 | 1999-08-03 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) compositions |
US6271203B1 (en) | 1994-07-07 | 2001-08-07 | Xoma Corporation | Anti-protozoan methods and materials |
US5646114A (en) * | 1994-07-11 | 1997-07-08 | Xoma Corporation | Anti-protozoan methods |
US5610075A (en) * | 1995-01-17 | 1997-03-11 | Stahl-Rees; Marianne | Competitive electrochemiluminescence assays for endotoxins using a ruthenium label |
US5494896A (en) * | 1995-03-31 | 1996-02-27 | Xoma Corporation | Method of treating conditions associated with burn injuries |
US6025326A (en) * | 1995-07-07 | 2000-02-15 | Intrabiotics Pharmaceuticals, Inc. | Compositions and methods for the prevention and treatment of oral mucositis |
JP2001520631A (ja) * | 1995-07-20 | 2001-10-30 | ゾーマ コーポレイション | 抗真菌性ペプチド |
US5994306A (en) * | 1995-11-22 | 1999-11-30 | Intrabiotics Pharmaceuticals, Inc. | Fine-tuned protegrins |
US5741779A (en) * | 1996-05-10 | 1998-04-21 | Xoma Corporation | Antithrombotic materials and methods |
AU735058B2 (en) | 1996-05-10 | 2001-06-28 | Xoma Corporation | Therapeutic uses of BPI protein products for human meningococcemia |
AU736096B2 (en) * | 1996-05-23 | 2001-07-26 | Xoma Corporation | Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma |
WO1997044354A2 (en) | 1996-05-24 | 1997-11-27 | Regents Of The University Of Minnesota | Synthesis of soluble beta-sheet forming peptides |
US5916872A (en) * | 1996-07-24 | 1999-06-29 | Intrabiotics Pharmaceuticals, Inc. | Cyclic peptides having broad spectrum antimicrobial activity |
US5888973A (en) | 1996-08-09 | 1999-03-30 | Xoma Corporation | Anti-chlamydial uses of BPI protein products |
US6482796B2 (en) | 1996-11-01 | 2002-11-19 | Xoma Corporation | Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients |
US6093573A (en) * | 1997-06-20 | 2000-07-25 | Xoma | Three-dimensional structure of bactericidal/permeability-increasing protein (BPI) |
US5990082A (en) * | 1997-10-22 | 1999-11-23 | Xoma Corporation | Uses of lipopolysaccharide binding protein |
US6013631A (en) * | 1998-06-19 | 2000-01-11 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) deletion analogs |
WO2000042994A2 (en) * | 1999-01-21 | 2000-07-27 | North Shore-Long Island Jewish Research Institute | Inhibition of bacterial dissemination |
US6107460A (en) * | 1999-03-01 | 2000-08-22 | The Board Of Regents Of The University Of Oklahoma | Antimicrobial peptides and methods of use thereof |
WO2001036478A2 (en) * | 1999-11-19 | 2001-05-25 | Hyseq, Inc. | Methods and compositions relating to bactericidal/permeability increasing factor-like polypeptides and polynucleotides |
AU2003211163A1 (en) | 2002-02-20 | 2003-09-09 | Regents Of The University Of Minnesota | Partial peptide mimetics and methods |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3987797A (en) * | 1974-02-25 | 1976-10-26 | Ethicon, Inc. | Antimicrobial sutures |
DE2652636A1 (de) * | 1976-11-19 | 1978-05-24 | Hans Uwe Dr Rer Nat Wolf | Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung |
US4143423A (en) * | 1977-10-25 | 1979-03-13 | Sternlieb Jack J | Surgical lubricants |
CH668554A5 (de) * | 1984-04-09 | 1989-01-13 | Sandoz Ag | Liposomen welche polypeptide mit interleukin-2-aktivitaet enthalten sowie verfahren zu ihrer herstellung. |
US4923854A (en) * | 1986-01-22 | 1990-05-08 | The Liposome Company, Inc. | Solubilization of hydrophobic materials using lysophospholipid |
US5073171A (en) * | 1989-01-12 | 1991-12-17 | Eaton John W | Biocompatible materials comprising albumin-binding dyes |
US5089274A (en) * | 1989-02-14 | 1992-02-18 | Incyte Pharmaceuticals, Inc. | Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders |
WO1991004019A1 (en) * | 1989-09-12 | 1991-04-04 | The Regents Of The University Of California | Therapeutic peptides and proteins |
-
1991
- 1991-09-27 US US07/766,566 patent/US5234912A/en not_active Expired - Fee Related
-
1992
- 1992-09-28 WO PCT/US1992/008234 patent/WO1993005797A1/en active IP Right Grant
- 1992-09-28 AU AU26997/92A patent/AU664206B2/en not_active Ceased
- 1992-09-28 CA CA002119262A patent/CA2119262C/en not_active Expired - Fee Related
- 1992-09-28 JP JP5506407A patent/JPH07502490A/ja active Pending
- 1992-09-28 DE DE69327516T patent/DE69327516T2/de not_active Expired - Fee Related
- 1992-09-28 EP EP93906309A patent/EP0610445B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US5234912A (en) | 1993-08-10 |
EP0610445A1 (en) | 1994-08-17 |
DE69327516D1 (de) | 2000-02-10 |
DE69327516T2 (de) | 2000-05-25 |
CA2119262C (en) | 2002-06-04 |
EP0610445A4 (en) | 1995-03-15 |
EP0610445B1 (en) | 2000-01-05 |
AU2699792A (en) | 1993-04-27 |
AU664206B2 (en) | 1995-11-09 |
WO1993005797A1 (en) | 1993-04-01 |
CA2119262A1 (en) | 1993-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07502490A (ja) | 殺菌性/透過性増大タンパク質および脂質担体を含有する組成物、その製造方法、およびそれらの使用 | |
KR100240385B1 (ko) | 재조합 bpi 단백질, bpi 단백질의 용도 및 그의 제조방법 | |
Hoess et al. | Crystal structure of an endotoxin‐neutralizing protein from the horseshoe crab, Limulus anti‐LPS factor, at 1.5 A resolution. | |
US5308834A (en) | Treatment of endotoxin-associated shock and prevention thereof using a BPI protein | |
US5334584A (en) | Recombinant, non-glycosylated bpi protein and uses thereof | |
JP2966923B2 (ja) | リポ多糖関連グラム陰性細菌感染を治療するための殺菌性/透過性増強タンパク質またはその生物学的に活性な類縁体の使用 | |
CN101155825B (zh) | 抗微生物六肽 | |
AU2009309477B2 (en) | Leukolectins and uses thereof | |
JPH11501636A (ja) | 医薬組成物 | |
JPH07507213A (ja) | 消化器デフェンシン,そのcDNA配列及び製造方法並びにその使用 | |
DK2563806T3 (en) | Human leukolectiner and uses thereof | |
JPH11503006A (ja) | カチオン性ペプチドの製造方法 | |
KR20110030554A (ko) | 항아밀로이드 면역원성 조성물, 방법 및 용도 | |
JPH09500269A (ja) | 殺菌性/透過性が増大したグリコシル化及び非グリコシル化タンパク質及びその製造方法 | |
EP1644410A1 (en) | Sushi peptide multimer | |
CZ303409B6 (cs) | Zkrácený a mutovaný lidský chemokin | |
JPH09512168A (ja) | 敗血症の治療用ヘパリン結合タンパク質およびその製造方法 | |
WO1996011700A1 (en) | Reduction of mammalian neoplasms with phospholipase a2 activatiing substances | |
KR20120022453A (ko) | 신규한 md-2 결합 폴리펩타이드 및 이의 용도 | |
WO2006028497A2 (en) | Active recombinant human lysozyme | |
WO2023030407A1 (zh) | 靶向夏科-莱登结晶蛋白的多肽及其应用 | |
WO2000012717A1 (fr) | Nouveau gene de lysozyme humain, polypeptide codant pour celui-ci et leur procede de preparation | |
WO2022164823A2 (en) | Inhibition of degranulation of neutrophil cells in covid-19 patients | |
CN101153056A (zh) | 一种重组抗癌肽及其制备方法和其应用 | |
JPH1014581A (ja) | ウサギ型マクロファージ・コロニー刺激因子及びこれをコードするdna断片 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20040226 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20040408 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20041020 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20041101 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051109 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051116 |